01—Abstract
Summary
Summary of the 8-K filed February 21, 2025. Cited figures are marked; the original filing is the authoritative source.
On February 21, 2025, HP Inc. (HPQ) reported in a Current Report on Form 8-K that its Board of Directors expanded the size of the Board and elected Gianluca Pettiti as a director, effective the same day.
Mr. Pettiti is Executive Vice President and President, Life Sciences, Diagnostics and Applied at Thermo Fisher Scientific Inc. The Board determined he is independent under New York Stock Exchange listing standards and the Company's Corporate Governance Guidelines, and appointed him to the Finance, Investment and Technology Committee and the HR and Compensation Committee. He will receive standard non-employee director compensation, pro-rated for his first partial year, including an annual cash retainer of $105,000a (which may instead be taken in fully vested shares) and an annual equity retainer of $220,000 in fully vested shares. The same day, the Board adopted amendments to the Company's Amended and Restated Bylaws, solely to increase the number of authorized directorships from 14 to 15 to accommodate Mr. Pettiti's appointment.
The amended and restated Bylaws are filed as Exhibit 3.1 to the report. The filing contains no information on financial results, operations, or guidance. For investors, the report is a governance update: a board seat added and filled by an independent director with life sciences industry experience, and a minor bylaw change tied to that appointment.
02—Key points
Key Highlights
- Gianluca Pettiti, Executive Vice President and President, Life Sciences, Diagnostics and Applied at Thermo Fisher Scientific Inc., was elected to HP Inc.'s Board of Directors effective February 21, 2025.
- The Board determined Mr. Pettiti is independent under NYSE listing standards and the Company's Corporate Governance Guidelines.
- Mr. Pettiti was appointed to the Finance, Investment and Technology Committee and the HR and Compensation Committee.
- Non-employee directors receive an annual cash retainer of $105,000 (which may be taken in fully vested shares) and an annual equity retainer of $220,000 in fully vested shares; Mr. Pettiti's first-year amounts will be pro-rated.
- Board meeting fees of $2,000 apply for each meeting attended beyond ten per Board year, and $2,000 for each committee meeting beyond ten per committee per Board year.
- The Board amended the Bylaws solely to increase the authorized number of directorships from 14 to 15, effective February 21, 2025.
- The filing reports no financial results, operating metrics, or guidance.
03—Questions
Frequently Asked Questions
Who is the new director and does he have any related-party interests?
Gianluca Pettiti is Executive Vice President and President, Life Sciences, Diagnostics and Applied at Thermo Fisher Scientific Inc. The filing states there are no arrangements or understandings with any other person under which he was selected, and he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Is the new director considered independent?
Yes. The Board has determined that Mr. Pettiti qualifies as an independent director under the New York Stock Exchange listing standards and the director independence standards in the Company's Corporate Governance Guidelines.
What committees will the new director serve on, and how is he compensated?
He was appointed to the Finance, Investment and Technology Committee and the HR and Compensation Committee. As a non-employee director, he will receive the standard director compensation: an annual cash retainer of $105,000 (which may be taken in fully vested shares) and an annual equity retainer of $220,000 in fully vested shares, with amounts pro-rated for his first partial year of service.
Why did the Company amend its Bylaws?
The Board amended the Amended and Restated Bylaws solely to increase the number of authorized directorships from 14 to 15 to accommodate Mr. Pettiti's appointment. The amendments are effective February 21, 2025, and the amended Bylaws are filed as Exhibit 3.1.
04—Continue